Retinitis Pigmentosa: Causes, Symptoms, and Treatment

What is Retinitis Pigmentosa?

The retina is a thin layer of light-sensitive tissue lining the back of the eye. Its fundamental role is to convert incoming light into electrical signals that are transmitted via the optic nerve to the brain, where they are interpreted as visual images. Without a properly functioning retina, vision is impossible.

Retinitis pigmentosa (RP) is the collective term for a group of rare, inherited eye diseases that progressively affect the retina. The retina contains specialized photoreceptor cells, primarily rods and cones, that respond to light.

• Rods are responsible for vision in low-light and night conditions, and for peripheral vision
• Cones are concentrated in the central retina (macula) and are responsible for sharp, detailed, daytime vision and color perception

For normal vision, these cells must work in close coordination. In retinitis pigmentosa, genetic mutations disrupt the normal functioning of these photoreceptor cells, leading to their progressive degeneration and death. The result is a gradual, irreversible loss of vision.

RP symptoms typically begin during childhood or adolescence but progress at highly variable rates depending on the specific genetic mutation involved. It is important to note that no curative treatment currently exists for retinitis pigmentosa. Therapy is therefore aimed at maximizing visual function at each stage of the disease and supporting the patient’s quality of life and independence.

---

Causes

Retinitis pigmentosa is a genetic disease caused by mutations (errors) present in the DNA from birth. It represents the most common inherited retinal dystrophy, affecting approximately:

• 1 in 4,000 people in the United States
• 1 in 5,000 people worldwide

An estimated 1.5 million people are affected globally.

Genetic Mutations

RP can result from mutations in more than 100 different genes, each encoding proteins essential for the survival and function of photoreceptor cells or the adjacent retinal pigment epithelium (RPE). If we think of DNA as an instruction manual for the body, each gene represents a chapter dedicated to a specific function. Errors in these chapters lead to faulty protein production and ultimately to photoreceptor cell death.

The typical disease course reflects the underlying biology: rod photoreceptors (responsible for night and peripheral vision) degenerate first. Over time, the widespread loss of rods creates a hostile metabolic environment for the adjacent cone cells, which subsequently degenerate as well, even though cones may not carry the primary mutation. This explains why night blindness and peripheral vision loss typically precede the loss of central vision in RP patients.

Inheritance Patterns

Retinitis pigmentosa can be inherited in several ways:

• In autosomal recessive RP, both parents carry one mutated copy of a gene (without being affected themselves), and a child must inherit two mutated copies to develop the disease.
• In autosomal dominant RP, a single mutated copy inherited from one affected parent is sufficient to cause the disease.
• In X-linked RP, the mutation is carried on the X chromosome. Males (who have only one X chromosome) are more severely affected, while carrier females may show mild symptoms or none at all. This accounts for why males are affected slightly more often than females overall.

The risk of transmitting RP to children varies depending on the inheritance pattern. Genetic counseling is strongly recommended for all affected individuals and their families before planning a pregnancy, to understand the specific risks and available reproductive options.

Non-Genetic Causes

In rarer cases, retinitis pigmentosa-like presentations may result from:

• Drug-induced retinal toxicity: certain medications, such as hydroxychloroquine (used for lupus and rheumatoid arthritis) and thioridazine, can cause pigmentary retinopathy resembling RP
• Infectious causes: congenital rubella, syphilis, and other infections have been associated with secondary pigmentary retinopathy
• Traumatic eye injuries

Associated Syndromes

In approximately 20–30% of cases, RP occurs as part of a broader syndrome involving other organ systems. The most notable examples include:

• Usher syndrome: RP combined with sensorineural hearing loss. It is the most common cause of combined deaf-blindness.
• Bardet–Biedl syndrome: RP with obesity, polydactyly, renal anomalies, and cognitive impairment
• Refsum disease: RP with peripheral neuropathy and elevated plasma phytanic acid levels (potentially treatable with dietary modification)
• Kearns–Sayre syndrome: RP with mitochondrial myopathy and cardiac conduction defects

---

Symptoms

Early Symptoms

The most common and often earliest symptom of retinitis pigmentosa is the loss of night vision (nyctalopia), which typically develops during childhood or adolescence. Because young children may lack a point of comparison, parents may first notice the problem by observing:

• Unusual difficulty moving in dim light or darkness
• Reluctance to go out at night
• Frequent stumbling or bumping into objects in low-light environments
• Slower adaptation when moving from a bright to a dark room

Progressive Vision Loss

As the disease advances, patients experience a characteristic pattern of visual deterioration:

1. Loss of peripheral (side) vision: difficulty perceiving objects and people at the edges of the visual field. This progresses gradually, constricting the visual field from the outside inward.
2. Tunnel vision occurs when peripheral vision narrows severely, leaving only a small central area of vision, like looking through a narrow tube.
3. Loss of central vision: In the later stages, even the remaining central vision may be affected. However, complete blindness is relatively uncommon in RP.

The rate of progression varies enormously between individuals, even within the same family carrying the same mutation. Some patients retain useful central vision well into their 50s or 60s, while others experience more rapid deterioration.

Additional Visual Symptoms

• Photophobia: increased sensitivity to bright light. Patients may find glare particularly uncomfortable.
• Impaired color vision: difficulty distinguishing colors, particularly in advanced stages.
• Photopsia is an abnormal perception of flashing lights, flickering, or sparkling that some patients describe. In a minority of cases, this can progress to visual hallucinations, which are more commonly associated with Charles Bonnet syndrome in low-vision patients.
• Reduced contrast sensitivity, which means difficulty distinguishing objects from their background.

Summary of Symptom Progression

RP typically affects both eyes (bilateral). Unilateral cases are extremely rare and anecdotal.

---

Complications

Beyond the progressive vision loss, a profoundly life-altering event in itself, retinitis pigmentosa also brings additional important complications. These must be actively anticipated and managed.

Ocular Complications

• Cataracts, particularly posterior subcapsular cataracts, develop in a significant proportion of RP patients. These cataracts can accelerate functional visual decline, but surgical removal often improves vision meaningfully.
• Cystoid macular edema (CME) is fluid accumulation in the central retina, known as the macula. This condition causes additional blurring of central vision. It can be treated with carbonic anhydrase inhibitors, such as acetazolamide or dorzolamide eye drops.
• Myopia (nearsightedness) is more prevalent in RP patients than in the general population.

Psychological and Social Complications

The psychological impact of a progressive, incurable visual disability must not be underestimated. It is very common for patients, along with their families, to experience:

• Anxiety, especially when tied to concerns about the speed of progression and future independence.
• Depression, often tied to the inevitable limitations of the condition, can arise from factors such as loss of driving ability, occupational changes, and social restrictions.
• Social isolation.
• Grief, a natural response to progressive loss.

Proactive psychological support, including referral to a mental health professional familiar with chronic illness and disability, is an integral component of comprehensive RP care. Patient support groups and organizations specializing in visual impairment can also provide invaluable peer support and practical resources.

Adaptive and Safety Considerations

Once the diagnosis is established, the prognosis becomes relatively predictable, allowing the patient and family to plan ahead. Practical adaptations to maximize independence and safety include:

• Maintaining a stable, uncluttered home environment with consistent furniture placement
• Installing additional lighting in work and living areas
• Learning orientation and mobility techniques with professional support
• Exploring assistive technology (screen readers, magnification software, talking devices)
• Transitioning away from driving as peripheral vision narrows (in most jurisdictions, driving with significantly restricted visual fields is prohibited for safety reasons)

---

Diagnosis

An ophthalmologist can diagnose retinitis pigmentosa through a comprehensive eye examination. The diagnostic process is largely painless and involves several components:

1. Fundoscopy (Dilated Eye Examination)

The physician instills dilating eye drops into the eye to widen the pupil, then uses an ophthalmoscope or slit-lamp biomicroscope to observe the retina directly (fundus examination). In RP, characteristic findings include:

• Bone-spicule pigmentation: dark, spidery pigment deposits in the peripheral retina. This hallmark finding gives the disease its name.
• Retinal vessel attenuation, or narrowing of the retinal arterioles.
• Waxy pallor of the optic disc (optic nerve head).
• Macular changes, which occur in advanced cases.

2. Electroretinography (ERG)

This is one of the most important objective tests for RP. Electroretinography measures the electrical response of the retina to light stimuli, assessing the function of both rod and cone photoreceptors. In RP, ERG responses are characteristically reduced or absent. This occurs even before significant symptoms develop, making ERG a valuable tool for early diagnosis and monitoring.

3. Visual Field Testing

Perimetry (visual field testing) quantifies the extent of peripheral vision loss and monitors progression over time. This is essential both for diagnosis and for assessing functional impact, driving eligibility, and disability evaluations.

4. Optical Coherence Tomography (OCT)

OCT uses light waves to produce high-resolution cross-sectional images of the retinal layers. It is particularly useful for:

• Detecting cystoid macular edema (a treatable complication)
• Measuring retinal thickness and monitoring structural changes over time
• Evaluating the integrity of the ellipsoid zone (a marker of photoreceptor health)

5. Genetic Testing

Molecular genetic testing is increasingly available and clinically important for:

• Confirming the diagnosis in atypical cases
• Identifying the specific mutation or mutations involved is critical for genetic counseling and determining inheritance risk.
• Guiding eligibility for gene therapy clinical trials (which are mutation-specific).
• Family screening.

---

Treatment

Currently, no treatment exists that can halt or reverse the progression of retinitis pigmentosa. Management focuses on:

1. Maximizing remaining visual function
2. Treating manageable complications
3. Supporting patient independence and quality of life
4. Monitoring for emerging therapies

1. Optical Aids and Low Vision Rehabilitation

• Sunglasses with UV and blue light filtering are routinely recommended to protect the remaining photoreceptors from potentially harmful light exposure, which may accelerate degeneration.
• Low vision aids, such as magnifiers, telescopic lenses, and high-contrast materials, can significantly improve daily functioning.
• Electronic assistive devices, such as screen readers, smartphones with accessibility features, and smart home technology, provide essential support for many users.
• Orientation and mobility training, essential for maintaining independence as vision narrows, plays a crucial role in daily life.

2. Treatment of Cystoid Macular Edema

Cystoid macular edema, when present, can be treated with:

• Oral or topical carbonic anhydrase inhibitors (for example, acetazolamide or dorzolamide) may improve central visual acuity.
• Intravitreal anti-VEGF injections, used in selected cases.

3. Cataract Surgery

When posterior subcapsular cataracts develop and significantly reduce vision, surgical removal can result in meaningful visual improvement. This is one of the few interventions that can genuinely improve vision in RP patients.

4. Vitamin A Supplementation

Some studies have suggested that high-dose vitamin A palmitate (15,000 IU/day) may slow the rate of rod photoreceptor degeneration in certain forms of RP. However:

• The evidence remains inconclusive and debated. A systematic review has not found robust confirmation of efficacy.
• High-dose vitamin A carries risks, including hepatotoxicity (liver damage), requiring regular liver function monitoring
• It is contraindicated during pregnancy due to teratogenic risks
• It must not be combined with vitamin E supplements, which have been shown to potentially worsen RP in some studies

Vitamin A supplementation should therefore be considered only on a case-by-case basis, in consultation with a retinal specialist familiar with the evidence.

Important: Never begin high-dose vitamin A supplementation without medical supervision. Excessive vitamin A is toxic and potentially harmful.

5. Gene Therapy

Voretigene neparvovec (Luxturna), approved by the FDA in 2017 and by the EMA in 2018, represents a landmark breakthrough: the first approved gene therapy for an inherited retinal disease. It is specifically indicated for patients with confirmed biallelic RPE65 gene mutations (a specific subtype of RP and Leber congenital amaurosis), who must retain sufficient viable retinal cells.

The therapy involves a single subretinal injection of a viral vector carrying a functional copy of the RPE65 gene. Clinical trials demonstrated significant improvement in light sensitivity and functional vision in treated patients.

However, RPE65-associated RP represents only a small fraction (~1–2%) of all RP cases. For the vast majority of patients with other gene mutations, gene therapies remain experimental and in clinical trial phases.

6. Retinal Prostheses (Bionic Eye)

The Argus II retinal prosthesis (Second Sight Medical Products) was approved for severe RP in the US and Europe. It uses a camera mounted on glasses to capture images, which are processed and transmitted as electrical impulses to an electrode array implanted on the retinal surface, bypassing degenerated photoreceptors. It can restore rudimentary light and motion perception in profoundly blind RP patients, though it does not restore normal vision.

7. Emerging and Investigational Therapies

Active research areas include:

• Additional gene therapies targeting other RP-associated genes (e.g., RPGR, CNGB3, CNGA3)
• Stem cell therapy, which aims to replace degenerated photoreceptors or RPE cells
• Neuroprotective agents, such as CNTF (ciliary neurotrophic factor), are designed to slow photoreceptor cell death regardless of the underlying mutation
• Optogenetic therapy: introducing light-sensitive proteins into surviving inner retinal cells to restore light sensitivity
• Antisense oligonucleotides: for specific mutation types

Patients and families are encouraged to enquire about clinical trials through registries such as ClinicalTrials.gov and organizations such as the Foundation Fighting Blindness.

---

Sources and Bibliography

• Retinitis Pigmentosa – Teri B. O’Neal; Euil E. Luther. StatPearls, NCBI
• National Eye Institute (NIH) – Retinitis Pigmentosa
• American Academy of Ophthalmology – What Is Retinitis Pigmentosa?
• Hartong DT, Berson EL, Dryja TP – Retinitis pigmentosa. Lancet, 2006. PubMed
• Berson EL et al. – Vitamin A supplementation for retinitis pigmentosa – systematic review. Cochrane Database of Systematic Reviews, 2013. PubMed
• FDA – Voretigene Neparvovec (Luxturna) Approval
• Foundation Fighting Blindness – Retinitis Pigmentosa
• Verbakel SK et al. – Non-syndromic retinitis pigmentosa. Progress in Retinal and Eye Research, 2018. PubMed